| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 8 | +0.00% | +7.88% | +2.46% | +5.42% | +5.75% | — |
| 14d | 8 | +0.00% | +13.82% | +3.48% | +10.34% | +6.92% | — |
| 30d | 8 | +0.00% | +10.39% | +9.98% | +31.98% | +31.98% | — |
| 60d | 8 | +0.00% | +30.55% | +2.82% | +24.91% | +24.91% | — |
| 90d | 8(7 pending) | +0.00% | +81.33% | +13.09% | +68.24% | +68.24% | — |
| 180d | 8(8 pending) | — | — | — | — | — | — |
| 1y | 8(8 pending) | — | — | — | — | — | — |
| 2y | 8(8 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 6,500 | $87.52 | $568.9K | 1,834 | Jul 1, 2026 | Jul 2, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASE Chief Medical Officer | 8,334 | $27.46 | $228.9K | 8,334 | Jul 1, 2026 | Jul 2, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 1,834 | $88.34 | $162.0K | 0 | Jul 1, 2026 | Jul 2, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE Chief Medical Officer | 8,334 | — | — | 305,000 | Jul 1, 2026 | Jul 2, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE Chief Medical Officer | 8,333 | — | — | 313,334 | Jun 3, 2026 | Jun 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 8,333 | $75.00 | $625.0K | 0 | Jun 3, 2026 | Jun 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASE Chief Medical Officer | 8,333 | $27.46 | $228.8K | 8,333 | Jun 3, 2026 | Jun 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 400 | $75.37 | $30.1K | 0 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASE Chief Medical Officer | 78,333 | $27.46 | $2.15M | 78,333 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 5,059 | $74.60 | $377.4K | 400 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 19,656 | $70.61 | $1.39M | 37,371 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE Chief Medical Officer | 78,333 | — | — | 321,667 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 21,306 | $69.53 | $1.48M | 57,027 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 12,777 | $72.94 | $932.0K | 15,817 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 8,777 | $71.56 | $628.1K | 28,594 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 10,358 | $73.74 | $763.8K | 5,459 | May 1, 2026 | May 1, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASE Chief Medical Officer | 7,958 | $21.66 | $172.4K | 7,958 | Apr 1, 2026 | Apr 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE Chief Medical Officer | 7,958 | — | — | 87,542 | Apr 1, 2026 | Apr 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 7,958 | $50.00 | $397.9K | 0 | Apr 1, 2026 | Apr 3, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 140,000 | — | — | 140,000 | Jan 9, 2026 | Jan 13, 2026 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 95,500 | — | — | 95,500 | Jan 15, 2025 | Jan 17, 2025 ↗ | View → |
| SYRE SPYRE THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 400,000 | — | — | 400,000 | Oct 1, 2024 | Oct 1, 2024 ↗ | View → |